Nautilus Biotechnology, Inc. (NAUT)

2.8200 +0.1300 (+4.83%) 收市：04:00PM EDT

Nautilus Biotechnology, Inc.

2701 Eastlake Avenue East
Seattle, WA 98102
United States
206 333 2001
https://www.nautilus.bio

版塊: Healthcare
行業: Biotechnology
全職員工: 163

高階主管

名稱	頭銜	支付	行使價	出生年份
Mr. Sujal M. Patel	Co-Founder, CEO, President, Secretary & Director	827.24k	無	1975
Dr. Parag Mallick Ph.D.	Co-Founder, Chief Scientist & Director	562.8k	無	1978
Ms. Anna Mowry	CFO & Treasurer	519.21k	無	1984
Ms. Mary E. Godwin	Senior Vice President of Operations	無	無	1959
Mr. Matthew B. Murphy ESQ.	General Counsel	382.64k	無	1965
Mr. Chris Blessington	Vice President of Corporate Marketing & Communications	無	無	無
Ms. Gwen E. Weld	Chief People Officer	390.97k	無	1958
Mr. Nick A. Nelson	Chief Business Officer & Senior VP of Business Development	無	無	1984
Dr. Subra Sankar Ph.D.	Senior Vice President of Product Development	38.47k	無	1960

截止 2023年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. It also offers proteome analysis system, a high-resolution optical imaging system for integrated fluidics and liquid handling sub-system. In addition, the company provides sample preparation, flow cells, multi-affinity probe reagents, and instrument buffers system to perform multi-cycle analysis runs. Nautilus Biotechnology, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.

公司管治

截至 2024年5月1日 止，Nautilus Biotechnology, Inc. 的 ISS 管治質素評分為 8。 Pillar 分數正在審核中：8；董事會：5；股東權利：8；現金賠償：9。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。